Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

Alpha Tau signs MOU for potential pancreatic cancer trial with Korea's top oncology center.

What the company is saying

Alpha Tau Medical Ltd. is announcing the signing of a memorandum of understanding with Samsung Medical Center in Seoul for a potential clinical trial of its Alpha DaRT therapy in pancreatic cancer patients. The company frames this as a strategic step toward expanding Alpha DaRT’s reach to cancer patients globally, emphasizing the prestige of SMC, which is ranked fifth worldwide and first in Korea in oncology. CEO Uzi Sofer highlights the potential for the pancreatic cancer program to span six countries across North America, Europe, the Middle East, and Asia, though no concrete agreements beyond this MOU are disclosed. The announcement underscores the severity of pancreatic cancer in Korea, referencing 9,748 new cases in 2023 and a five-year survival rate of just 17.0%. SMC’s Pancreatobiliary Cancer Center is described as a high-volume surgical program, having performed over 4,000 pancreatectomies between 2008 and 2025. The company’s tone is optimistic, but all clinical, regulatory, and commercial outcomes are presented as contingent on future approvals and reviews. No financial terms, trial protocols, or operational commitments are included.

What the data suggests

The announcement provides epidemiological data showing 9,748 Koreans diagnosed with pancreatic cancer in 2023 and a five-year relative survival rate of 17.0%, the lowest among all cancers in Korea. SMC’s Pancreatobiliary Cancer Center has performed more than 4,000 pancreatectomies for pancreatic cancer between 2008 and 2025, indicating significant institutional experience. The only realised milestone is the signing of a non-binding MOU; no regulatory or ethics approvals, trial initiation, or patient enrollment have occurred. There is no disclosure of financial figures, operational budgets, or clinical trial protocols. The evidence supports that Alpha Tau has secured a high-profile institutional partner for potential collaboration, but all clinical and commercial benefits remain speculative. The data is strong on institutional credibility and disease burden but absent on financial impact or execution progress.

Analysis

The announcement is framed in highly positive terms, emphasizing the significance of the MOU with a top-ranked cancer center and the potential global reach of Alpha Tau's pancreatic cancer program. However, the only realised milestone is the signing of a non-binding MOU; all clinical, regulatory, and commercial benefits are contingent on future approvals and trial initiation, with no timeline or protocol disclosed. The majority of key claims are forward-looking, including the potential for a multi-country program and the intended clinical impact of Alpha DaRT, but there is no evidence of trial commencement, patient enrollment, or clinical results. No financial, operational, or profitability metrics are disclosed, and there is no mention of capital outlay or funding requirements at this stage. The language inflates the signal by implying imminent progress and broad impact, while the actual evidence supports only an early-stage collaboration. The data supports a weak_positive signal due to the strategic partnership, but the gap between narrative and realised progress is material.

Risk flags

• ●The MOU is non-binding and explicitly subject to regulatory and ethics committee approvals, so there is no guarantee that a clinical trial will proceed. This introduces significant execution risk, as regulatory or institutional hurdles could delay or halt progress.
• ●No financial terms, operational commitments, or trial protocols are disclosed, making it impossible to assess the capital requirements, funding risks, or operational feasibility of the proposed trial. This lack of detail increases uncertainty for investors.
• ●All clinical and commercial outcomes are forward-looking and contingent on future approvals and successful trial execution. The absence of any disclosed timeline or milestones means investors have no visibility on when, or if, value realisation may occur.
• ●The announcement relies heavily on the prestige and operational scale of Samsung Medical Center, but institutional partnership alone does not guarantee trial success, regulatory approval, or commercial adoption of Alpha DaRT.

Bottom line

Alpha Tau’s MOU with Samsung Medical Center signals early-stage interest in a potential pancreatic cancer trial, backed by strong institutional credibility and clear epidemiological need. The announcement is limited to a non-binding agreement with no disclosed financial terms, trial protocols, or regulatory approvals, so all benefits are speculative and long-dated. The company’s narrative leans heavily on the prestige of its partner and the scale of the disease, but there is a material gap between the aspirational language and realised progress. Investors should treat this as a preliminary signal of intent rather than an actionable catalyst. The most important takeaway is that while the partnership could open doors in a high-need market, tangible value will depend on regulatory approvals, trial initiation, and eventual clinical results, none of which are imminent or guaranteed.

Announcement summary

(NASDAQ:DRTS) Alpha Tau Medical Ltd. announced the signing of a memorandum of understanding (MOU) in Seoul, South Korea, with Samsung Medical Center (SMC) regarding a potential clinical trial in pancreatic cancer patients. The initiation of any such trial is subject to regulatory and ethics committee approvals. In 2023, 9,748 Koreans were diagnosed with pancreatic cancer, which is now the fourth leading cause of cancer death in South Korea, and has a five-year relative survival rate of 17.0%, the lowest among all cancers in the country. Fewer than one in six patients are diagnosed while the cancer is still confined to the pancreas, and more than four in ten are diagnosed only after it has already spread to distant organs. SMC is ranked fifth in the world and number one in Korea in oncology, and its Pancreatobiliary Cancer Center has performed more than 4,000 pancreatectomies for pancreatic cancer between 2008 and 2025. Uzi Sofer, CEO of Alpha Tau, stated that the MOU with SMC is an important step in the company's goal to bring Alpha DaRT to cancer patients globally, and that the pancreatic cancer program could potentially span six countries across North America, Europe, the Middle East, and Asia. Hee-Chul Kim, EVP of Samsung Medical Center and General Director of Samsung Comprehensive Cancer Center (SCCC), commented that pancreatic cancer remains one of the most challenging cancers to treat and that the MOU will help explore new possibilities for patients, with a careful review of the clinical application of Alpha DaRT. Alpha Tau Medical Ltd. was founded in 2016 and focuses on the research, development, and potential commercialization of Alpha DaRT for the treatment of solid tumors. Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed for highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources, aiming to primarily affect the tumor and spare healthy tissue. SCCC has expanded its capabilities since opening in 2008, establishing several specialized centers and achieving ICHOM Level 1 accreditation in 2026. In 2023, SCCC signed MOUs with Gustave Roussy and Charité, and in 2026 signed an MOU with EORTC. SMC was ranked fifth in the world and first in Korea in oncology in Newsweek’s World’s Best Specialized Hospitals 2027.

Disagree with this article?